New Anti-inflammatory Treatment Strategy in Alzheimer's Disease

Access this Article


    • Uz Tolga UZ Tolga
    • The Psychiatric Institute, West Side VA Medical Center, Department of Psychiatry, University of Illinois at Chicago
    • MANEV Hari
    • The Psychiatric Institute, West Side VA Medical Center, Department of Psychiatry, University of Illinois at Chicago


Numerous reports have indicated that patients suffering from inflammatory diseases(e.g., arthritis)who take anti-inflammatory medication have a reduced risk of developing Alzheimer’s disease(AD).Thus, the first generation of anti-inflammatory cyclooxygenase(COX)inhibitors, such as aspirin and indomethacin, have been tested as potential therapeutics in AD.Because the inhibition of COX-1 is also known to cause tissue damage in the gastrointestinal system from the resultant reduced cytoprotection, selective COX-2 inhibitors are being investigated and tested clinically as potentially better therapeutics for AD patients.However, such drugs may also trigger unwanted effects;for example, the COX-2 inhibitors, which reduce the production of one type of eicosanoids, the prostaglandins, may increase the production of other eicosanoids;i.e., the leukotriene B<SUB>4</SUB>(LTB<SUB>4</SUB>), which is one of the most potent endogenous chemotactic/inflammatory factors.LTB<SUB>4</SUB> production is initiated by the enzyme 5-lipoxygenase(5-LOX).The expression of the 5-LOX gene is upregulated during neurodegeneration and with aging.In spite of the fact that 5-LOX and leukotrienes are major players in the inflammation cascade, their role in AD pathobiology/therapy has not been extensively investigated.We propose that the 5-LOX inflammatory cascade may take part in the process of aging-associated neurodegenerative diseases, and we point to the role of 5-LOX in neurodegeneration and discuss its relevance for anti-inflammatory therapy of AD.


  • The Japanese Journal of Pharmacology

    The Japanese Journal of Pharmacology 82(2), 85-94, 2000-02-01

    The Japanese Pharmacological Society

References:  109

  • 1 / 2
  • 1 / 2

Cited by:  1


  • NII Article ID (NAID)
  • Text Lang
  • Article Type
    Journal Article
  • ISSN
  • NDL Article ID
  • NDL Source Classification
  • NDL Call No.
  • Data Source
    CJP  CJPref  NDL  J-STAGE 
Page Top